Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 17/20 | 0.62 |
| ▸ | KDR | P35968 | 15/20 | 0.62 |
| ▸ | HCK | P08631 | 14/20 | 0.51 |
| ▸ | SRC | P12931 | 11/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL3589433 | 0.99 | LCK (0.61) | LCKKDRHCKSRCMEN1 | |
| SCHEMBL3596191 | 0.87 | LCK (0.80) | LCKKDRHCKSRCMEN1 | |
| SCHEMBL13503292 | 0.70 | LCK (0.62) | LCKKDRHCKSRCMEN1 | |
| SCHEMBL4171810 | 0.70 | LCK (0.71) | LCKKDRHCKSRCMEN1 | |
| SCHEMBL27775870 | 0.69 | LCK (0.69) | LCKKDRHCKSRC | |
| SCHEMBL13503295 | 0.68 | LCK (0.62) | LCKKDRHCKSRCMEN1 | |
| SCHEMBL4175200 | 0.67 | LCK (0.74) | LCKKDRHCKSRCMEN1 | |
| SCHEMBL3587794 | 0.67 | LCK (0.81) | LCKKDRHCKSRCMEN1 | |
| SCHEMBL4177792 | 0.66 | LCK (0.65) | LCKKDRHCKSRCMEN1 | |
| SCHEMBL4167899 | 0.65 | LCK (0.66) | LCKKDRHCKSRCMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029636-A1 | Lck inhibitors | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029636-A1 | Lck inhibitors | LCK, ZAP70, FYN | LCK 1/4885KDR 1630/4885HCK 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.